Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prolyl Endopeptidase-Like Facilitates the alpha-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF

Full text
Author(s):
Santos, Gabriel S. [1] ; Oyadomari, William Y. [1] ; Carvalho, Elizangela A. [1] ; Torquato, Ricardo S. [2] ; Oliveira, Vitor [1]
Total Authors: 5
Affiliation:
[1] Univ Fed Sao Paulo, Dept Biophis, Escola Paulista Med, BR-04039032 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Biochem, Escola Paulista Med, BR-04039032 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: BIOMOLECULES; v. 10, n. 6 JUN 2020.
Web of Science Citations: 0
Abstract

The aggregation of alpha-synuclein (alpha-Syn) is a characteristic of Parkinson's disease (PD). alpha-Syn oligomerization/aggregation is accelerated by the serine peptidase, prolyl oligopeptidase (POP). Factors that affect POP conformation, including most of its inhibitors and an impairing mutation in its active site, influence the acceleration of alpha-Syn aggregation resulting from the interaction of these proteins. It is noteworthy, however, that alpha-Syn is not cleaved by POP. Prolyl endopeptidase-like (PREPL) protein is structurally related to the serine peptidases belonging to the POP family. Based on the alpha-Syn-POP studies and knowing that PREPL may contribute to the regulation of synaptic vesicle exocytosis, when this protein can encounter alpha-Syn, we investigated the alpha-Syn-PREPL interaction. The binding of these two human proteins was observed with an apparent affinity constant of about 5.7 mu M and, as in the alpha-Syn assays with POP, the presence of PREPL accelerated the oligomerization/aggregation events, with no alpha-Syn cleavage. Furthermore, despite this lack of hydrolytic cleavage, the serine peptidase active site inhibitor phenylmethylsulfonyl fluoride (PMSF) abolished the enhancement of the alpha-Syn aggregation by PREPL. Therefore, given the attention to POP inhibitors as potential drugs to treat synucleinopathies, the present data point to PREPL as another potential target to be explored for this purpose. (AU)

FAPESP's process: 18/09158-0 - Prolyl oligopeptidase: structure-activity and secretion
Grantee:Vitor Marcelo Silveira Bueno Brandão de Oliveira
Support Opportunities: Regular Research Grants